Information Provided By:
Fly News Breaks for November 26, 2019
EOLS
Nov 26, 2019 | 07:24 EDT
As previously reported, SVB Leerink analyst Marc Goodman initiated coverage of Evolus with an Outperform rating and $25 price target. He is bullish on the sustainable growth of the broader U.S. aesthetics market and specifically believes the neurotoxins market will grow in the 7%-10% range to $2B in 2025. Evolus' Jeuveau is the fourth neurotoxin to enter the U.S. market, but "the first toxin that is really similar" to Allergan's (AGN) Botox, giving it a viable opportunity to become the number two player in the U.S. market in the next few years, Goodman contends. He also likes the management team and expects M&A over time to bring in additional aesthetics products.
News For EOLS From the Last 2 Days
EOLS
Apr 22, 2021 | 08:54 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Renalytix... To see the rest of the story go to thefly.com. See Story Here
EOLS
Apr 21, 2021 | 18:51 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGSQualtrics... To see the rest of the story go to thefly.com. See Story Here
EOLS
Apr 21, 2021 | 16:02 EDT
SVB Leerink, Stifel and Cantor are acting as joint bookrunning managers for the offering.